GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hangzhou Bio-Sincerity Pharma-Tech Co Ltd (SZSE:301096) » Definitions » Net Income From Continuing Operations

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Net Income From Continuing Operations : ¥287 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Hangzhou Bio-Sincerity Pharma-Tech Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Hangzhou Bio-Sincerity Pharma-Tech Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥50 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥287 Mil.

Hangzhou Bio-Sincerity Pharma-Tech Co Net Income From Continuing Operations Historical Data

The historical data trend for Hangzhou Bio-Sincerity Pharma-Tech Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Bio-Sincerity Pharma-Tech Co Net Income From Continuing Operations Chart

Hangzhou Bio-Sincerity Pharma-Tech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial 45.02 57.19 110.97 194.04 272.02

Hangzhou Bio-Sincerity Pharma-Tech Co Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.11 84.39 82.03 70.49 49.82

Hangzhou Bio-Sincerity Pharma-Tech Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥287 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hangzhou Bio-Sincerity Pharma-Tech Co Ltd (SZSE:301096) » Definitions » Net Income From Continuing Operations
Comparable Companies
SHSE:600713 SZSE:301507 SHSE:688176 SHSE:600666 SZSE:000411 SZSE:300109 SZSE:300006 SZSE:301281 SHSE:600613 SZSE:002198 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN
Traded in Other Exchanges
N/A
Address
611 Dongguan Road, 2nd Floor, Building 8, Jinsheng Technology Park, Binjiang District, Hangzhou, CHN
Website
https://www.hzbio-s.com
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a pharmaceutical technology research and development company. The company's business covers drug discovery, pharmaceutical research, clinical research, and registration application.

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Headlines

No Headlines